Quick Answer
Amphastar Pharmaceuticals, Inc. reported Net Income Loss of $98.09 million for the year ending 2025.
- Amphastar Pharmaceuticals, Inc. showed a decrease of -38.5% in Net Income Loss from 2024 to 2025.
- This data is from Amphastar Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Amphastar Pharmaceuticals, Inc.'s Net Income Loss has grown by 442.1%.
- Historical annual values: Fiscal year 2025: $98.09 million | Fiscal year 2024: $159.52 million | Fiscal year 2023: $137.55 million | Fiscal year 2022: $91.39 million | Fiscal year 2021: $62.12 million | Fiscal year 2020: $1.40 million | Fiscal year 2019: $48.94 million | Fiscal year 2018: -$5.74 million | Fiscal year 2017: $3.65 million | Fiscal year 2016: $9.82 million | Fiscal year 2015: -$2.79 million | Fiscal year 2014: -$10.70 million | Fiscal year 2013: $11.86 million | Fiscal year 2012: $18.09 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: